Stockscreener 앱 받기
2.705
6.92%
0.175
전일 마감가:
$2.53
열려 있는:
$2.59
하루 거래량:
313.34K
Relative Volume:
0.40
시가총액:
$215.38M
수익:
$70.14M
순이익/손실:
$-76.24M
주가수익비율:
-2.4369
EPS:
-1.11
순현금흐름:
$-57.06M
1주 성능:
-4.08%
1개월 성능:
-37.24%
6개월 성능:
-2.70%
1년 성능:
-15.47%
1일 변동 폭
$2.57
$2.71
1주일 범위
$2.515
$2.835
52주 변동 폭
$2.47
$6.08
Codexis Inc Stock (CDXS) Company Profile
명칭
Codexis Inc
전화
650-421-8100
주소
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
CDXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.705 | 215.38M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.43 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.17 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.60 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-29 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-07 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-08-07 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2021-04-12 | 개시 | Piper Sandler | Overweight |
| 2021-03-01 | 개시 | Stifel | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-10 | 개시 | The Benchmark Company | Buy |
| 2019-01-17 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 개시 | Stephens | Overweight |
| 2017-10-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-31 | 개시 | Jefferies | Buy |
| 2017-01-26 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 개시 | H.C. Wainwright | Buy |
모두보기
Codexis Inc 주식(CDXS)의 최신 뉴스
Codexis sees $261,350 stock acquisition by Opaleye management By Investing.com - Investing.com South Africa
Codexis sees $261,350 stock acquisition by Opaleye management - Investing.com India
Stocks of Codexis Inc (CDXS) are poised to climb above their peers - SETE News
Major Shareholder Makes Bold Move with Codexis Stock Purchase! - TipRanks
Codexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Advances - GuruFocus.com
Codexis Announces New Employment Inducement Grants - GlobeNewswire
Codexis grants equity to new hires under inducement plan - Investing.com India
New Hires at Codexis Receive Significant Equity Compensation Package - StockTitan
FY2025 EPS Estimates for Codexis Raised by Cantor Fitzgerald - Defense World
Codexis sees $172,273 stock purchase by Opaleye management - Investing.com
Codexis sees $172,273 stock purchase by Opaleye management By Investing.com - Investing.com South Africa
Things To Consider Before Buying Codexis Inc (NASDAQ: CDXS) - Stocks Register
Codexis at TD Cowen Conference: Enzymatic Innovation in siRNA Manufacturing - Investing.com
This trade activity should not be overlooked: Codexis Inc (CDXS) - SETE News
Codexis stock touches 52-week low at $2.55 amid market challenges - Investing.com Australia
Codexis Inc: Is CDXS Stock Worth Buying? - Stocks Register
Investor Network: Codexis, Inc. to Host Earnings Call - ACCESS Newswire
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Codexis (NASDAQ:CDXS investor three-year losses grow to 84% as the stock sheds US$93m this past week - Simply Wall St
When Will Codexis, Inc. (NASDAQ:CDXS) Become Profitable? - Yahoo Finance UK
Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Codexis, Inc. (NASDAQ:CDXS) Q4 2024 Earnings Call Transcript - Insider Monkey
Codexis shares tumble as Q4 results miss estimates, outlook disappoints - Investing.com India
Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ... - Yahoo Finance
Codexis Reports 2024 Results, Eyes Growth in 2025 - TipRanks
Codexis: Balancing Revenue Shortfalls and Strategic Advances Amid Cautious Optimism - TipRanks
Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results - GlobeNewswire
Codexis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Codexis Q4 2024 misses earnings, stock slips By Investing.com - Investing.com South Africa
Earnings call transcript: Codexis Q4 2024 misses earnings, stock slips - Investing.com
Codexis: Q4 Earnings Snapshot - The Advocate
Codexis shares tumble as Q4 results miss estimates, outlook disappoints By Investing.com - Investing.com Australia
Codexis, Inc. to Host Earnings Call - ACCESS Newswire
Codexis Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Specialty Enzymes Market to Expand at 7.5% CAGR, Reaching USD 10.7 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Codexis announces the approval of equity grants for new employees - MSN
Codexis (CDXS) to Release Quarterly Earnings on Wednesday - Defense World
Codexis to Participate in TD Cowen 45th Annual Health Care Conference - The Manila Times
Jordan Seigel - The Globe and Mail
Exclusive: Codexis Unveils Future Roadmap at Major Healthcare Conference - StockTitan
Baillie Gifford & Co. Sells 119,775 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Synthetic Biology Market Top Companies StudyBota Biosciences - openPR
abrdn plc Reduces Stake in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Strategic Talent Investment: Codexis Awards 66.5K Shares in Employee Equity Package - StockTitan
Codexis Inc (CDXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.28%
0.80%
자본화:
|
볼륨(24시간):